Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immune modulation therapy - Celldex Therapeutics Inc

Drug Profile

Research programme: immune modulation therapy - Celldex Therapeutics Inc

Alternative Names: LOR-A04; LOR-S01; LOR-S03; αCD27xαPD-L1 bispecific antibodies

Latest Information Update: 28 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lorantis
  • Developer Celldex Therapeutics Inc; Lorantis
  • Class Antineoplastics; Bispecific antibodies; DNA; Immunotherapies; Proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic asthma; Cancer; Immunological disorders; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection; Viral infections

Most Recent Events

  • 28 May 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
  • 21 Apr 2018 Preclinical trials in Cancer in United Kingdom (Parenteral)
  • 12 Oct 2005 Lorantis has been acquired by Celldex Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top